Do you want to read an article? Please log in or register.
Why are patients with non-small cell lung cancer in stage I-IIIA considered inoperable? A registry-based study from the capital region of Denmark
Lung Cancer
Related content
Lung Cancer
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J Clin Med
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group
doi: 10.3390/jcm14030945
Lung Cancer
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
Lung Cancer
Supiot R, Gherardi A, du Manoir de Juaye L, Doghri O, Sivignon M, Duruisseaux M, Chouaid C
doi: 10.1016/j.lungcan.2025.108885
Lung Cancer
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study
Lancet Respir Med
Lu S, Vynnychenko O, Kulyaba Y, Kuchava V, Ibrahim A, Moiseenko F, Arslan C, Nguyen DT, Petrovic M, Cicin I, Bibichadze K, Cil T, Shi J, Olmez OF, Gogishvili M, Artac M, Nguyen HG, Cornfeld M, Tian C, Munteanu MC, Sette CVM, Bondarenko I, POD1UM-304 Study Team
doi: 10.1016/S2213-2600(25)00209-7
Lung Cancer
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study
Clin Lung Cancer
Koster KL, Yohasenan S, Pakmak AS, Mark M, Metaxas Y, Lips C, Hitz F, Leskow P, Ludwig C, Putora PM, Glatzer M, Schneider T, Caviezel C, Mader T, Mousavi M, Blum M, Früh M, Joerger M
doi: 10.1016/j.cllc.2025.05.010
Interstitial Lung DiseaseLung Cancer
Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study
Thorax
Karayama M, Miyashita K, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Inui N, Suda T
doi: 10.1136/thorax-2025-223430
Lung Cancer
Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study
Sci Rep
Wang L, Wang R, Wei Z, Wang Y, Chen H, Dong B, Hu X, Ma H, Wang Z, Feng W, Li P, Lin X, Xu Y
doi: 10.1038/s41598-024-73177-2
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
RECOMMENDED
Lung Cancer
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T
doi: 10.1016/j.lungcan.2025.108671
Lung Cancer
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Clin Lung Cancer
Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM
doi: 10.1016/j.cllc.2025.05.014